恶性腹水双途径联合化疗的临床疗效评价

目的：评价双途径联合化疗治疗恶性腹水的临床疗效及不良反应。方法：根据瘤细胞类型选择药物，静脉与腹腔联合用药。结果：本方法治疗食管癌、胃癌、原发性肝癌、大肠癌、卵巢癌所致恶性腹水的总有效率依次为‘76．9％、85.l％、27.3％、75.l％和88．9％，腹水平均控制时间分别为46．3、5l.2、60．6、53．7和48．9天，平均生存期分别为13．4、10．8、5.2、ll.6和12.7个月。不良反应发生率，中、高度发热为35．5％，恶心呕吐为100％，轻、中度腹痛为77．7％；白细胞普遍下降，肝肾功能损害不显著。结论：双途径联合化疗是目前治疗恶性腹水有效、可行的一种方法。

Evaluation of clinic effects of the two-way combinated Chemotherapy of malignant ascites

Objective:To evaluate the both clinic effects and adverse reaction of malignant asciles was treated by the two-way comhinated chemotherapy. Methods:To select drugs according to the types of tumorcell, take intravenous injection and abdominal administration. Results:The total efficiency of treating malignant ascites that it result in carcinoma of esophagus, stomach, liver, large intestine and ovary was successively 76. 9% , 85. 1% , 27. 3% , 75. 1% and 88. 9% , respectively. The average controlling time of ascites was 46. 3 , 51.2, 60. 6, 53. 7 and 48. 9 days respectively. The average living deadline of the patients was 13. 4, 10. 8 , 5. 2, 11.6, 12.7 months respectively. The occurred rate of adverse reaction, middle-high degree fever was 35.5% , nausea and vomiting was 100% , light-middle degree abdominal pain was 77. 7% , WBC declined, the damage of the liver and kidney function was not obvious. Conclusion: The two-way combinated chemotherapy is the effective and practical way that treats malignant ascites at present.